ArticleInternational journal of cancer2014
Kaposi's Sarcoma in HIV-infected patients in South Africa: Multicohort study in the antiretroviral therapy era.
Article in International journal of cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 60 citations in OpenAlex.
- Kaposi sarcoma in the era of immunodeficiency: challenges and opportunities for treatment and prevention.Annals of medicine and surgery (2012) · 2026Article
- Virus infections and cancers: from mechanisms to therapeutics.Molecular biomedicine · 2026Review
- HIV-associated Kaposi sarcoma: Advanced disease and high mortality of patients referred to a multidisciplinary clinic in South Africa, 2022-2024.Southern African journal of HIV medicine · 2026Article
- Article
- Article
- The Trends and Risk Factors of AIDS-Defining Cancers and Non-AIDS-Defining Cancers in Adults Living with and without HIV: A Narrative Review.Journal of cancer epidemiology · 2024Review
- Prognostic analysis of cutaneous Kaposi sarcoma based on a competing risk model.Scientific reports · 2023Article
- Review
- Safety and effectiveness of gemcitabine for the treatment of classic Kaposi's sarcoma without visceral involvement.Therapeutic advances in medical oncology · 2022Article
- Characteristics and Treatment Response of Patients with HIV Associated Kaposi's Sarcoma in Central Kenya.HIV/AIDS (Auckland, N.Z.) · 2022Article
- Cancer in HIV-positive and HIV-negative adolescents and young adults in South Africa: a cross-sectional study.BMJ open · 2021Article
- Chronic viral hepatitis, HIV infection and Non-Hodgkin lymphomas in West Africa, a case-control study.International journal of cancer · 2021Article
- Feasibility of Rapid Case Ascertainment for Cancer in East Africa: An Investigation of Community-Representative Kaposi Sarcoma in the Era of Antiretroviral Therapy.Cancer epidemiology · 2021Article
- Immunodeficiency and Cancer in 3.5 Million People Living With Human Immunodeficiency Virus (HIV): The South African HIV Cancer Match Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Comparative transcriptome analysis of endemic and epidemic Kaposi's sarcoma (KS) lesions and the secondary role of HIV-1 in KS pathogenesis.PLoS pathogens · 2020Article
- Epidemiology of Kaposi's sarcoma in Zambia, 2007 - 2014.Malawi medical journal : the journal of Medical Association of Malawi · 2020Article
- Prevalence of Kaposi's sarcoma-associated herpesvirus and transfusion-transmissible infections in Tanzanian blood donors.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2020Article
- Real-world use of chemotherapy for Kaposi's sarcoma in a large community-based HIV primary care system in Kenya.BMC cancer · 2020Article
- A retrospective review of patients with Kaposi's sarcoma in Botswana.International journal of dermatology · 2019Article
- Similar Immunological Profiles Between African Endemic and Human Immunodeficiency Virus Type 1-Associated Epidemic Kaposi Sarcoma (KS) Patients Reveal the Primary Role of KS-Associated Herpesvirus in KS Pathogenesis.The Journal of infectious diseases · 2019Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
9 authors at 7 institutions in 3 countries.
Funding
Abstract
The incidence of Kaposi's Sarcoma (KS) is high in South Africa but the impact of antiretroviral therapy (ART) is not well defined. We examined incidence and survival of KS in HIV-infected patients enrolled in South African ART programs. We analyzed data of three ART programs: Khayelitsha township and Tygerberg Hospital programs in Cape Town and Themba Lethu program in Johannesburg. We included patients aged >16 years. ART was defined as a regimen of at least three drugs. We estimated incidence rates of KS for patients on ART and not on ART. We calculated Cox models adjusted for age, sex and time-updated CD4 cell counts and HIV-1 RNA. A total of 18,254 patients (median age 34.5 years, 64% female, median CD4 cell count at enrolment 105 cells/μL) were included. During 37,488 person-years follow-up 162 patients developed KS. The incidence was 1,682/100,000 person-years (95% confidence interval [CI] 1,406-2,011) among patients not receiving ART and 138/100,000 person-years (95% CI 102-187) among patients on ART. The adjusted hazard ratio comparing time on ART with time not on ART was 0.19 (95% CI 0.13-0.28). Low CD4 cell counts (time-updated) and male sex were also associated with KS. Estimated survival of KS patients at one year was 72.2% (95% CI 64.9-80.2) and higher in men than in women. The incidence of KS is substantially lower on ART than not on ART. Timely initiation of ART is essential to prevent KS and KS-associated morbidity and mortality in South Africa and other regions in Africa with a high burden of HIV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.